Gynecologic Cancers: Key Takeaways from Cantor's 2nd Annual Oncology Symposium

Research evidence excerpt

Gynecologic Cancers: Key Takeaways from Cantor's 2nd Annual Oncology Symposium

Biotechnology

EQUITY RESEARCH Industry Report

May 26, 2026

Gynecologic Cancers: Key Takeaways from Cantor's

Research Analysts:

Li Watsek 2nd Annual Oncology Symposium

212-915-1221

Li.Watsek@cantor.com We hosted a highly interactive gynecologic oncology panel at our Cantor

Carter Gould Oncology Symposium last week. Two KOLs are from leading academic

212-915-1794 centers in NYC who have extensive experience treating ovarian and Carter.Gould@cantor.com

endometrial cancers. Both histologies have witnessed a proliferation of Daniel Bronder, PhD

212-610-2433 ADCs. The discussion focused on the newly approved therapies in ovarian

Daniel.Bronder@cantor.com cancer, the growing role of ADCs in PROC (platinum-resistant ovarian

cancer), and how TCEs may fit into future sequencing strategies.

PROC remains the highest unmet need in ovarian cancer

●Frontline therapy (carbo/paclitaxel +/- bev) works very well with

~80-90% achieving clinical remission in ovarian cancer; our panelists

believe replacing the 1L backbone is unlikely in the near term.

●Emerging therapies are focused maintenance settings, recurrent

PSOC (platinum-sensitive ovarian cancer), and PROC where outcomes

remain poor with standard chemotherapy. Most patients eventually

develop platinum resistance after platinum rechallenge.

●For patients with FRα high expression (~30-40% of high-grade serous

ovarian cancers), the SoC is Elahere. Ocular tox is a major adoption

barrier. If FRα-negative, patients will be tested for HER2 positivity.

~10-15% of patients with HER2 expression is eligible for Enhertu. If a

patient is double-negative, a single-agent chemo or chemo+bev may

be used.

●The bar in PROC is currently low; most trials have single-agent